Description
Background information
The MAGE-A3 belongs to the melanoma antigen family and all members encode proteins with a high sequence similarity of up to 80% to each other. The expression of MAGE-A3 is restricted to the germ cells of testis but absent in somatic tissue except tumor cells.
In diagnostic application the protein is used for the identification of tumors like melanoma, non-small-lung cancer and hematologic malignancies. This makes MAGE-A3 to potent tumor-marker for immunotherapy.1,2
Applications
The MACS GMP PepTivator MAGE-A3 is suitable for in vitro stimulation of MAGE-A3-specific CD4+ and CD8+ effector and memory T cells.
Adoptive transfer of MAGE-A3-specific T cells or vaccination with MAGE-A3-pulsed dendritic cells may be an effective tool for the treatment of MAGE-A3-expressing malignancies.
This product has not yet been tested in conjunction with the CliniMACS Cytokine Capture System (IFN-gamma).
Quality statement
MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.
Disclaimer
MACS GMP Products are for ex vivo cell processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative.
Overview
The MACS GMP PepTivator MAGE-A3 is a peptide pool that consists mainly of 15-mer peptides. It has been developed for efficient in vitro stimulation and subsequent isolation of MAGE-A3-specific CD4+ and CD8+ T cells.
